相关实验视频

Updated: May 9, 2026

Roux-en-Y Gastric Bypass Operation in Rats

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

减肥手术后减肥的最小重要差异:提高BODY-Q的解释性

Farima Dalaei^1,2,3, Phillip J Dijkhorst⁴, Sören Möller^3,5

¹Research Unit of Plastic Surgery, Odense University Hospital, Odense, Denmark.

Clinical obesity

|May 22, 2024

概括

这项研究确定了BODY-Q的最小重要差异 (MID),这是评估减肥手术结果的工具. 这些发现为解释减肥手术中患者报告的结果提供了指导,提高了临床效用.

科学领域:

减肥手术研究成果研究结果
患者报告的结果措施 (PROMs)
临床实用性评估临床实用性评估

背景情况:

BODY-Q是患者报告的结果衡量标准,对于评估减肥手术结果至关重要.
解释BODY-Q分数是具有挑战性的,因为缺乏确定的指导方针.
这限制了其在评估治疗有效性的临床实用性.

研究的目的:

确定 BODY-Q. 的最小重要差异 (MID).
为解释减肥手术患者的得分变化提供基准.
为了增强 BODY-Q.Q. 的临床应用.

主要方法:

未来收集来自丹麦和荷兰的减肥手术患者的BODY-Q数据.
利用两种基于分布的方法来估计MID:基线得分的0.2标准偏差和标准化响应变化的平均值.
分析了来自2253名参与者的数据 (5476次评估) 跨越各种减肥手术.

主要成果:

据估计,与健康相关的生活质量 (HRQL) 的MID在基线时为1至4.
预计MID的外观尺度在基线从2到8不等.
对BODY-Q HRQL和外观尺度的变化推的MID是3到8,有助于解释治疗效应.

结论:

该研究成功确定了BODY-Q.的MID值.
这些MID值为解读腹腔外科手术后的BODY-Q分数提供了关键指导.
这些发现被推用于评估治疗效果和改善临床决策.

关键词:

身体-QQ 身体-QQ 减肥手术减肥手术是什么代谢性手术是代谢性手术.最少重要的临床差异.最小的重要差异.测量患者报告的结果.减肥手术减肥手术减肥手术

更多相关视频

Sleeve Gastrectomy in Mice using Surgical Clips

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

A Protocol for Roux-en-Y Gastric Bypass in Rats using Linear Staplers

A Protocol for Roux-en-Y Gastric Bypass in Rats using Linear Staplers

Published on: August 21, 2021

相关概念视频

Drug Dosing: Obese Patients

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...